Namchun Cho

Namchun Cho is a Senior Investment Director in the Venture Capital / Investment Professionals group at Aju IB Investment Co., Ltd. (아주IB투자), a Seoul-based firm that traces its roots to 1974 as the first venture capital company established in Korea. The firm listed on the KOSDAQ market (ticker 027360) in November 2018 and today engages in both venture capital and private equity/mezzanine investing, backing SMEs and venture companies and providing IPO, M&A, and secondary support.

Before joining Aju IB, Cho worked at Korea Investors Service, Inc. (KIS), one of Korea's major credit-rating agencies — a background that lends analytical, credit-and-valuation rigor to his investment work. He is a graduate of Kyunghee University. External financial databases (e.g., MarketScreener) index him as a senior executive/managing director at the firm, consistent with a long-tenured investment leadership role.

Aju IB is led by CEO Kim Ji-won and is organized into Venture Capital, Global Investment, Private Equity, and Accelerator units. Cho sits within the domestic venture investment side of that organization. The firm is widely regarded in the Korean market as a "bio powerhouse," and much of its recent headline performance has come from life-sciences investing, both in Korea and through its U.S. arm.

• Invests as an institutional VC across early-stage to growth and pre-IPO rounds — not as an individual angel — with typical venture checks reported in the ~USD 0.9M–2.6M range.
• Strong bio/healthcare orientation at the firm level: immune-system platform technologies, oncology/therapeutics, diagnostics, and medical devices are recurring themes.
• Also pursues advanced-technology / deep-tech opportunities and global (especially U.S.) deals via subsidiary Solasta Ventures.
• Values companies with differentiated, defensible technology and a credible path to IPO or strategic exit — reflecting the firm's IPO/M&A support capabilities and Cho's credit-analysis background from Korea Investors Service.